Active clinical trials for "Pneumonia"

COVID-19 is an infectious disease caused by a virus called SARS-CoV-2. The spread rate and mortality rate of the virus have had a significant impact on global health and economic systems. Comprehensive treatment and supportive care are required to help COVID-19 patients recover. During the treatment of COVID-19, the respiratory system of patients may be affected, and measures need to be taken to support respiratory function. Currently, awake prone positioning(APP) is an effective method for treating respiratory failure when mechanical ventilation is not feasible or unavailable. In the prone position, the patient's face is facing the ground, the chest is sinking, and the abdomen is rising. This posture can improve alveolar ventilation and blood flow distribution, reduce pulmonary edema and pulmonary vascular resistance. In addition, the prone position can also improve the coordination of respiratory muscles, promote pulmonary expectoration, and increase functional residual capacity. Although the prone position has been widely used, there is still some controversy over when to use it. Some studies have shown that using the APP for early-stage COVID-19 patients can reduce mortality rates and respiratory dependence time, while others believe that using the APP in the later stages may increase the risk of lung injury. Therefore, it is necessary to further study when to use the APP and its impact on treatment effectiveness and safety. Such research may need to consider multiple factors, such as the patient's clinical symptoms, the severity of lung lesions, lung function indicators, and the duration of using the prone position. Determining the optimal time to use the APP will help guide clinical physicians to better apply this treatment strategy in the treatment of COVID-19 patients. In addition, the prone position can also be used in the treatment of other respiratory system diseases, so relevant research can also provide references and inspiration for the treatment of other diseases. The goal of this observational study is to learn about the details which might optimize the effect of APP in COVID-19 patients. The main questions it aims to answer are: The optimal time to start in the prone position the optimal duration of APP treatment the strategies to improve the tolerance of the awake prone position

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

The purpose of this study to assess the effectiveness of no antibiotic treatment for fast breathing, community-acquired childhood pneumonia in a malaria-endemic region of Malawi.

The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of standard of care antibiotic treatment.

the management of Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) gram-negative bacilli (GNB) represent a real therapeutic dilemma in intensive care unit (ICU). Colistin remains an effective agent against MDR GNB. However, because of its side effects, mainly nephrotoxicity, other modalities than the intra venous (IV) route should be tried. Several recent data emphasize the interest of inhaled route. The investigators purpose was to evaluate the effectiveness and systemic toxicity of aerosolized colistin in ventilator associated pneumonia.

This study evaluates the addition of tobramycin inhalation treatment to standard intravenous therapy in the treatment of ventilator associated pneumonia.

The purpose of this study is to evaluate the pharmacokinetics and lung penetration of intravenous Ceftolozane/tazobactam in critically ill participants.

To determine, in children hospitalized with pneumonia, if an extended duration of oral antibiotics (10 days) will be superior to a shorter duration (3 days) of antibiotics in improving clinical outcomes. Secondary Aims: Describe the prevalence of respiratory viruses and bacteria at presentation. Investigate the depression, anxiety and stress scores (DASS21) and quality of life scored (QOL) by parents of the children during admission, pre-discharge and post discharge and at follow-ups.

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.

Overall objective of the study is to compare the use of SPECT in radiotherapy treatment planning with standard CT-based radiotherapy for stage I-III non-small-cell lung cancer patients